EUVIMEDEUVIMED entdecken
Fallbericht

Iatrogenic ANA: An emerging source of expensive diagnostic confusion

Hammad Ali iD, Connor R Buechler, Oneeb Sanaullah, Alexandria Lucas, Kristine L Lohr

Lupus · 2023-02 · 32 (2) · 299-300

DOI: 10.1177/09612033221144600 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Lupus, online erschienen am 06.12.2022. Verfasst von Hammad Ali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Division of Internal Medicine, 4530University of Kentucky, Lexington, KY, USA. Hauptthemen laut MEDLINE: Antibodies, Antinuclear, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intravenous immune globulin (IVIg) therapy has been shown to be useful in a multitude of disorders. IVIg is produced from pooled human plasma; therefore, autoantibodies found in the general population are also present in IVIg and transferred to those being transfused. This can prove a particular hazard for screening and diagnostic tests based on autoantibodies. We present a patient who was found to have a positive antinuclear antibody (ANA) titer after multiple IVIg transfusions, resulting in diagnostic confusion and unnecessary workup. A 45-year-old gentleman was diagnosed with atypical CIDP, initiated on a course of IVIg, and sent for inpatient rehabilitation. However, recovery was complicated by multiple readmissions for recurrent weakness, and as part of the workup for other etiologies, an ANA was found to be positive. Sub-serologies and paraneoplastic autoantibody panel were negative. In the absence of clinical symptoms, we recommended continued monitoring and repeat ANA testing 6 months after the last dose of IVIg; as any drug needs 5 half-lives to be eliminated from the body. Clinicians should consider any recent IVIg treatments when evaluating the pre-test probability of detecting an underlying connective tissue disease with ANA screening. Indiscriminate ANA levels in patients recently given IVIg lead to unnecessary and expensive further testing and consultation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, AntinuclearLupus Erythematosus, SystemicMaleHumansMiddle AgedImmunoglobulins, IntravenousAutoantibodiesIatrogenic Disease

Stichwörter der Autor:innen

Intravenous immune globulinantinuclear antibodyautoimmunityfalse positive antibodies

Substanzen

Antibodies, AntinuclearImmunoglobulins, IntravenousAutoantibodies

Autor:innen und Institutionen

  • Department of Rheumatology, Division of Internal Medicine, 4530University of Kentucky, Lexington, KY, USA.
  • Department of Medicine and Dermatology, 144447University of Minnesota, Minneapolis, MN, USA.
  • Department of Medicine, 23128Robert Packer Hospital, Geisinger University, Sayre, PA, USA.
  • College of Medicine, 12252University of Kentucky, Lexington, KY, USA.

ORCID-Profile: Hammad Ali

Zitieren

APA

Ali, H., Buechler, C. R., Sanaullah, O., Lucas, A., & Lohr, K. L. (2023). Iatrogenic ANA: An emerging source of expensive diagnostic confusion. Lupus, 32(2), 299-300. https://doi.org/10.1177/09612033221144600

Vancouver

Ali H, Buechler CR, Sanaullah O, Lucas A, Lohr KL. Iatrogenic ANA: An emerging source of expensive diagnostic confusion. Lupus. 2023;32(2):299-300. doi:10.1177/09612033221144600

BibTeX
@article{Ali2023,
  author = {Ali, Hammad and Buechler, Connor R and Sanaullah, Oneeb and Lucas, Alexandria and Lohr, Kristine L},
  title = {Iatrogenic ANA: An emerging source of expensive diagnostic confusion},
  journal = {Lupus},
  year = {2023},
  volume = {32},
  number = {2},
  pages = {299--300},
  doi = {10.1177/09612033221144600}
}
Kostenlos starten →